Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months

NCT ID: NCT02889497

Last Updated: 2016-09-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety,three batches consistency and immunity duration of the post-marketing inactivated Enterovirus Type 71 (EV71) vaccine in children aged 6-71 months.This study has two groups:safety observation group and immunogenicity observation group.20000 subjects will receive 2 doses vaccines and be observed for safety among 2 epidemic cycles of HFMD.In the immunogenicity observation group, 900 subjects will be randomly received 3 batches vaccines(2 doses),and blood sampled at days 0 and 56.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hand Foot and Mouth Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

300 subjects receive the first batch vaccine

300 subjects will be randomly received the first batch vaccine

Group Type EXPERIMENTAL

the first batch vaccine

Intervention Type BIOLOGICAL

300 subjects receive the second batch vaccine

300 subjects will be randomly received the second batch vaccine

Group Type EXPERIMENTAL

the second batch vaccine

Intervention Type BIOLOGICAL

300 subjects receive the third batch vaccine

300 subjects will be randomly received the third batch vaccine

Group Type EXPERIMENTAL

the third batch vaccine

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

the first batch vaccine

Intervention Type BIOLOGICAL

the second batch vaccine

Intervention Type BIOLOGICAL

the third batch vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 8 Months to 71 Months (Healthy Children or Infants);
* Providing the subjects' legal identity certificate (birth certificate , residence booklet or ID card) and vaccination certificate, legal guardians can provide legal identity proof (resident booklet or ID card) so that the doctor can determine the subject identity to complete recruitment program;
* The subjects' guardians are able to understand and sign the informed consent voluntary. Guardians have the ability to use the thermometer ,dividing ruler and can fill out the Diary card ,follow-up card according to requirements;
* Persist for a 24 months visit.If doubtful HFMD case happen,the subject's guardian should send the subject to the medical institutions at above the county level and report this case to the investigator.The subjects who participate immunogenicity observation group can receive sample collection including blood,throat swab or anal awab according to program requirements.

Exclusion Criteria

* Subject with clinical diagnosis or suspect HFMD(Especially the history of herpangina);
* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine;
* History of seizures,convulsions or twitching ;Family history of progressive neurological disease;
* Autoimmune disease or immunologic deficiency.Any prior administration of immunodepressant in last 6month;
* History of asthma,thyroid ablation,angioneurotic edema, diabetes mellitus or malignant tumour;
* Alienia,functional asplenia,or any condition that cause asplenia or splenectomy;
* Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder;
* Any acute disease or chronic disease attack in last 7 days;
* Any prior administration of blood products in last 3 month;
* Any prior administration of attenuated live vaccine in last 15 days , subunit or inactivated vaccines in last 7 days;
* Fever before vaccination, axillary temperature ﹥37.0℃;
* Attend Other vaccine or drug clinical trials concurrent in 6 months;
* Any condition that in the opinion of the investigator。

* Newly HFMD diagnosed patients after been enrolled;
* Any condition that in the opinion of the investigator or ethics committee think should be eliminated.
Minimum Eligible Age

6 Months

Maximum Eligible Age

71 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Chaoyang District Centre for Disease Control and Prevention

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

cycdc2016-6

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.